NASDAQ: KPRXKiora Pharmaceuticals Inc Stock
$2.63+0.02 (+0.77%)
Updated Jun 30, 2026
KPRX Price
$2.63
Fair Value Price
$2.03
Market Cap
$11.66M
52 Week Low
$1.76
52 Week High
$3.29
P/E
-0.99x
P/B
0.84x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.06M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.52
Operating Cash Flow
-$10M
Beta
0.92
Next Earnings
Aug 14, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KPRX Overview
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KPRX's potential to beat the market
- KPRX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important KPRX news, forecast changes, insider trades & much more!
KPRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KPRX ($2.63) is overvalued by 29.6% relative to our estimate of its Fair Value price of $2.03 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KPRX ($2.63) is not significantly undervalued (29.6%) relative to our estimate of its Fair Value price of $2.03 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KPRX due diligence checks available for Premium users.
Valuation
KPRX fair value
Fair Value of KPRX stock based on Discounted Cash Flow (DCF)
Price
$2.63
Fair Value
$2.03
Overvalued by
29.60%
KPRX ($2.63) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KPRX ($2.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.99x
Industry
16.41x
Market
8.51x
KPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.84x
Industry
5.44x
KPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KPRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.4M
Profit Margin
0%
KPRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$21.2M
Liabilities
$7.3M
Debt to equity
0.52
KPRX's short-term assets ($18.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KPRX's short-term assets ($18.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KPRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$5.4M
Financing
-$842.0
KPRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KPRX vs Biotech Stocks
Kiora Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.